Management of Nostril and Lip Abscess After Failed Bactrim Therapy

Immediate Surgical Drainage is Essential

For a cutaneous abscess involving the face (nostril and lip), incision and drainage is the primary and most critical treatment, and antibiotic therapy alone—regardless of the agent chosen—will fail without adequate surgical drainage. 1

The face represents a high-risk anatomic location where abscesses are difficult to drain completely and carry significant risk of complications including cavernous sinus thrombosis. 1 Your patient requires urgent surgical consultation for formal incision and drainage, not simply a change in antibiotics.

Why Bactrim Failed: Coverage Gaps for Facial Abscesses

Bactrim (trimethoprim-sulfamethoxazole) provides excellent coverage against community-associated MRSA but has zero activity against β-hemolytic streptococci, which are common pathogens in facial skin and soft tissue infections. 1

The nostril and lip region is colonized by both Staphylococcus aureus (including MRSA) and β-hemolytic streptococci (particularly Streptococcus pyogenes). 1 Bactrim monotherapy leaves streptococcal infections completely untreated, explaining the treatment failure.

Additionally, if this abscess developed as a complication of bacterial sinusitis, the causative organisms may include Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis—none of which are adequately covered by Bactrim. 2

Recommended Antibiotic Regimen After Drainage

Switch to high-dose amoxicillin-clavulanate 875 mg/125 mg twice daily for 7–10 days immediately after surgical drainage. 1, 2

This regimen provides:

Excellent coverage of β-hemolytic streptococci (the likely missed pathogen) 1
Coverage of MRSA-negative S. aureus (methicillin-sensitive strains) 1
Coverage of β-lactamase-producing organisms from potential sinus source (H. influenzae, M. catarrhalis) 2
Predicted clinical efficacy of 90–92% for complicated skin and soft tissue infections 2

The clavulanate component is essential because 30–40% of H. influenzae and 90–100% of M. catarrhalis produce β-lactamase, rendering plain amoxicillin ineffective. 2

Alternative Regimen if Penicillin Allergy

If the patient has a non-severe penicillin allergy (e.g., rash without anaphylaxis):

Cefuroxime-axetil, cefpodoxime-proxetil, or cefdinir for 10 days provides adequate streptococcal and staphylococcal coverage with negligible cross-reactivity risk. 1, 2

If the patient has a severe (Type I/anaphylactic) penicillin allergy:

Clindamycin 600 mg IV or PO three times daily for 7–14 days provides excellent gram-positive coverage including both MRSA and β-hemolytic streptococci. 1
Clindamycin is specifically recommended for facial abscesses in the difficult-to-drain category. 1

Do NOT use:

Bactrim alone (no streptococcal coverage) 1
Fluoroquinolones (inadequate streptococcal coverage and should be reserved for resistant infections) 1, 2
Azithromycin or other macrolides (20–25% resistance rates for both S. aureus and streptococci) 2

Hospitalization Criteria for Facial Abscesses

This patient requires hospitalization and IV antibiotics if any of the following are present: 1

Severe or extensive disease (multiple sites of infection—nostril AND lip qualifies)
Rapid progression in the presence of associated cellulitis
Signs of systemic illness (fever, tachycardia, hypotension)
Abscess in an area difficult to drain (face, hand, genitalia—nostril and lip both qualify)
Associated septic phlebitis (thrombosis of facial veins draining to cavernous sinus)
Lack of response to incision and drainage alone (this patient has already failed outpatient management)

Given that this patient has failed outpatient Bactrim therapy and has abscesses in two high-risk facial locations, hospitalization for IV antibiotics is strongly indicated. 1

Inpatient IV Antibiotic Regimen

For hospitalized patients with complicated facial SSTI, start IV vancomycin 15–20 mg/kg every 8–12 hours (target trough 15–20 mcg/mL) PLUS a β-lactam (cefazolin 1–2 g IV every 8 hours) to cover both MRSA and β-hemolytic streptococci. 1

Alternative IV options include:

Linezolid 600 mg IV or PO twice daily (covers both MRSA and streptococci) 1
Daptomycin 4 mg/kg IV once daily (for MRSA; add β-lactam for streptococcal coverage) 1
Clindamycin 600 mg IV three times daily (if local clindamycin resistance rate is <10%) 1

Continue IV therapy until clinical improvement (typically 48–72 hours), then transition to oral therapy to complete a 7–14 day total course. 1

Obtain Cultures Before Changing Antibiotics

Cultures from purulent drainage are mandatory in this patient because: 1

The patient has failed initial antibiotic treatment (Bactrim)
The patient has severe local infection (multiple facial sites)
There is concern for MRSA (given the need for Bactrim initially)

Send aerobic cultures with susceptibility testing to guide definitive antibiotic selection. 1 If the patient is immunocompromised or diabetic, also send fungal cultures. 3

Reassessment Timeline

Reassess at 48–72 hours after drainage and antibiotic switch: 1

If no improvement, consider:
- Inadequate drainage (may need repeat procedure or ENT consultation)
- Resistant organism (await culture results)
- Alternative diagnosis (fungal infection, vasculitis, malignancy)
- Underlying immunodeficiency 3

Reassess at 7 days: 2

If symptoms persist or worsen, obtain imaging (CT or MRI) to exclude:
- Deep space abscess (buccal space, masticator space)
- Osteomyelitis of facial bones
- Cavernous sinus thrombosis 3

Red Flags Requiring Urgent ENT/Infectious Disease Consultation

Immediately consult ENT and Infectious Disease if any of the following develop: 3

Visual changes or transient vision loss (suggests orbital or cavernous sinus involvement)
Proptosis or ophthalmoplegia (orbital cellulitis or abscess)
Severe headache or altered mental status (intracranial extension)
Cranial nerve deficits (cavernous sinus thrombosis)
Rapidly progressive cellulitis despite IV antibiotics
Necrotic tissue (suggests necrotizing fasciitis or mucormycosis in diabetics) 4

Underlying Sinus Infection Management

If the abscess developed as a complication of bacterial sinusitis (as suggested by your question), the sinusitis itself requires treatment: 2

First-line: Amoxicillin-clavulanate 875 mg/125 mg twice daily for 5–10 days (same regimen as for the abscess) 2
Adjunctive therapy: Intranasal corticosteroids (mometasone, fluticasone, or budesonide twice daily) to reduce mucosal inflammation 2, 5
Supportive measures: Saline nasal irrigation 2–3 times daily, analgesics, adequate hydration 2, 5

Reassess sinusitis at 3–5 days: 2

If no improvement, switch to a respiratory fluoroquinolone (levofloxacin 500 mg once daily for 10–14 days or moxifloxacin 400 mg once daily for 10 days) 2

Critical Pitfalls to Avoid

Do not prescribe antibiotics without surgical drainage for facial abscesses—antibiotics alone have a high failure rate regardless of the agent chosen. 1
Do not continue Bactrim monotherapy—it provides zero streptococcal coverage and will continue to fail. 1
Do not use azithromycin or other macrolides—resistance rates exceed 20–25% for both S. aureus and streptococci. 2
Do not delay hospitalization if the patient meets criteria—facial abscesses can rapidly progress to life-threatening complications including cavernous sinus thrombosis. 1, 3
Do not miss underlying immunodeficiency—recurrent or severe facial abscesses in an otherwise healthy adult should prompt evaluation for diabetes, HIV, or primary immunodeficiency. 3

What is the appropriate next step in management for a patient with nostril and lip abscesses following a sinus infection that has not responded to trimethoprim‑sulfamethoxazole (Bactrim)?

Help us tailor your experience